ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Sells $25,952.00 in Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) VP Meredith Cook sold 400 shares of the firm's stock in a transaction dated Monday, July 14th. The shares were sold at an average price of $64.88, for a total value of $25,952.00. Following the sale, the vice president owned 78,945 shares in the company, valued at approximately $5,121,951.60. The trade was a 0.50% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Meredith Cook also recently made the following trade(s):

• On Friday, June 13th, Meredith Cook sold 400 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $61.37, for a total value of $24,548.00.

ANI Pharmaceuticals Stock Performance

NASDAQ:ANIP traded up $0.23 during midday trading on Monday, reaching $65.19. 198,588 shares of the company traded hands, compared to its average volume of 319,041. ANI Pharmaceuticals, Inc. has a twelve month low of $52.50 and a twelve month high of $77.00. The firm has a market capitalization of $1.41 billion, a price-to-earnings ratio of -51.33 and a beta of 0.57. The company has a debt-to-equity ratio of 1.46, a current ratio of 2.66 and a quick ratio of 1.98. The company has a fifty day moving average price of $63.31 and a 200 day moving average price of $62.37.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last released its quarterly earnings data on Friday, May 9th. The specialty pharmaceutical company reported $1.70 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.37 by $0.33. ANI Pharmaceuticals had a positive return on equity of 21.35% and a negative net margin of 3.12%. The business had revenue of $197.12 million during the quarter, compared to analyst estimates of $179.75 million. During the same quarter in the previous year, the firm posted $0.82 EPS. The business's revenue for the quarter was up 43.4% compared to the same quarter last year. On average, analysts expect that ANI Pharmaceuticals, Inc. will post 3.86 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in ANIP. Voya Investment Management LLC raised its stake in shares of ANI Pharmaceuticals by 12.0% in the 1st quarter. Voya Investment Management LLC now owns 8,934 shares of the specialty pharmaceutical company's stock worth $598,000 after buying an additional 957 shares in the last quarter. Jane Street Group LLC bought a new stake in shares of ANI Pharmaceuticals in the 1st quarter worth $2,706,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in shares of ANI Pharmaceuticals by 0.9% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 48,322 shares of the specialty pharmaceutical company's stock worth $3,235,000 after buying an additional 423 shares in the last quarter. Woodline Partners LP bought a new stake in shares of ANI Pharmaceuticals in the 1st quarter worth $11,144,000. Finally, Parkman Healthcare Partners LLC bought a new stake in shares of ANI Pharmaceuticals in the 1st quarter worth $7,030,000. Institutional investors and hedge funds own 76.05% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on ANIP shares. HC Wainwright started coverage on ANI Pharmaceuticals in a research note on Thursday. They set a "buy" rating and a $84.00 price objective for the company. Guggenheim reiterated a "buy" rating and issued a $86.00 target price on shares of ANI Pharmaceuticals in a research report on Monday, May 12th. Truist Financial lifted their target price on ANI Pharmaceuticals from $62.00 to $65.00 and gave the stock a "hold" rating in a research report on Monday, April 21st. Finally, Wall Street Zen lowered ANI Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Thursday, April 24th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $78.88.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.